Timothy Fenske, MD, MS

Timothy S. Fenske, MD, MS, discusses the rationale for evaluating the role of standard auto-HCT in MCL given recent updates to the MCL treatment paradigm.

Timothy S. Fenske, MD, MS, discusses survival outcomes in patients with MCL who remained MRD positive following consolidative auto-HCT.

Timothy S. Fenske, MD, MS, details the rationale of a phase 3 trial assessing rituximab with or without ASCT in mantle cell lymphoma.

Timothy S. Fenske, MD, MS, discusses implications for data on the omission of auto-HCT in MCL after first CR and with undetectable MRD.

Timothy S. Fenske, MD, MS, shares outcomes from the phase 3 ECOG-ACRIN EA4151 trial of patients with mantle cell lymphoma after first MRD-negative CR.

Timothy Fenske, MD, MS, discusses the utility of next-generation BTK inhibitors in mantle cell lymphoma.

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses an ongoing study in the frontline treatment of mantle cell lymphoma.

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses targets under evaluation in mantle cell lymphoma.

Timothy Fenske, MD, MS, associate professor, Medical College of Wisconsin, discusses the future of daratumumab (Darzalex) in mantle cell lymphoma (MCL).

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses his recommendations for oncologists treating patients with mantle cell lymphoma (MCL) who are progressing on ibrutinib (Imbruvica).